Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 20/20 | 0.49 |
| ▸ | PPARA | Q07869 | 7/20 | 0.49 |
| ▸ | PPARG | P37231 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL944889 | 0.92 | PPARD (0.51) | PPARDPPARAPPARGMEN1ALDH1A1 | |
| SCHEMBL944128 | 0.87 | PPARD (0.55) | PPARDPPARAPPARGMEN1ALDH1A1 | |
| SCHEMBL943075 | 0.86 | PPARD (0.51) | PPARDPPARAPPARG | |
| SCHEMBL945495 | 0.84 | PPARD (0.50) | PPARDPPARAPPARG | |
| SCHEMBL12909777 | 0.84 | PPARD (0.53) | PPARDPPARAPPARG | |
| SCHEMBL946182 | 0.81 | PPARD (0.56) | PPARDPPARAPPARG | |
| SCHEMBL946259 | 0.81 | PPARD (0.57) | PPARDPPARAPPARGMEN1ALDH1A1 | |
| SCHEMBL945635 | 0.81 | PPARD (0.70) | PPARDPPARAPPARG | |
| SCHEMBL12909775 | 0.75 | PPARD (0.44) | PPARDPPARAPPARGMEN1ALDH1A1 | |
| SCHEMBL978946 | 0.75 | PPARD (0.47) | PPARDPPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2184277-B1 | ARYL PYRIMIDINE DERIVATIVES, PREPARATION METHODS AND PHARMACEUTICAL USES THEREOF | INST PHARM & TOXICOLOGY AMMS (CN) | 2015-07-01 | — | — | EP | claimed |
| US-8759355-B2 | Aryl pyrimidine derivatives, preparation methods and pharmaceutical uses thereof | INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. (CN) | 2014-06-24 | — | — | US | claimed |
| US-20110009427-A1 | ARYL PYRIMIDINE DERIVATIVES, PREPARATION METHODS AND PHARMACEUTICAL USES THEREOF | INSTITUE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA (CN) | 2011-01-13 | — | — | US | claimed |
| EP-2184277-A1 | ARYL PYRIMIDINE DERIVATIVES, PREPARATION METHODS AND PHARMACEUTICAL USES THEREOF | Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. China (CN) | 2010-05-12 | — | — | EP | claimed |
| EP-2184277-B1 | ARYL PYRIMIDINE DERIVATIVES, PREPARATION METHODS AND PHARMACEUTICAL USES THEREOF | INST PHARM & TOXICOLOGY AMMS (CN) | 2015-07-01 | — | — | EP | disclosed |
| US-8759355-B2 | Aryl pyrimidine derivatives, preparation methods and pharmaceutical uses thereof | INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. (CN) | 2014-06-24 | — | — | US | disclosed |
| US-20110009427-A1 | ARYL PYRIMIDINE DERIVATIVES, PREPARATION METHODS AND PHARMACEUTICAL USES THEREOF | INSTITUE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA (CN) | 2011-01-13 | — | — | US | disclosed |
| EP-2184277-A1 | ARYL PYRIMIDINE DERIVATIVES, PREPARATION METHODS AND PHARMACEUTICAL USES THEREOF | Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. China (CN) | 2010-05-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009427-A1 | ARYL PYRIMIDINE DERIVATIVES, PREPARATION METHODS AND PHARMACEUTICAL USES THEREOF | PPARD, PPARG, PPARA | PPARD 1/4885PPARA 3/4885PPARG 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.